Life Sciences & MOBs: Institutional Capital Still Chasing Innovation
By Majid Radaei, RadCRE · · Industry Insights
Despite wider market headwinds, institutional demand for life sciences and medical office buildings remains robust, with investment volume reaching $18.5 billion in 2023.
Institutional Capital Targets Life Sciences and Medical Office
In an environment marked by elevated interest rates and subdued transaction volumes across many commercial real estate sectors, life sciences and medical office buildings (MOBs) continue to attract significant institutional capital. These sectors are characterized by strong underlying fundamentals, including long lease terms, credit-worthy tenants, and strong demographic tailwinds, positioning them as defensive plays and growth opportunities for investors.
Life Sciences: Innovation Drives Resilient Demand
The life sciences sector, encompassing R&D facilities, laboratories, and biotech manufacturing, is experiencing a nuanced but ultimately resilient demand narrative. While venture capital funding for early-stage biotechs saw a dip in 2023 compared to peak 2021 levels, significant capital continues to pour into late-stage and established companies. This translates directly into demand for specialized real estate, particularly in innovation hubs like Boston/Cambridge, San Francisco Bay Area, and San Diego.
According to JLL's 2024 Life Sciences Outlook, venture capital funding for life sciences totaled $33.6 billion in 2023, down from $50.3 billion in 2022 but still significantly above pre-pandemic levels. This sustained funding underpins tenant expansion and absorption. Major deals continue to highlight investor confidence. For instance, in August 2023, BioMed Realty, a Blackstone-owned entity, acquired a 1.2 million-square-foot life sciences portfolio in Cambridge, MA, from Alexandria Real Estate Equities for an undisclosed sum, signaling continued belief in prime assets within core markets.
Medical Office Buildings: Essential Services & Demographic Strengths
Medical office buildings, another healthcare-related asset class, benefit from the non-discretionary nature of healthcare services and the aging demographics of the U.S. population. The demand for outpatient services continues to grow, driving strong occupancy rates and rent growth in well-located MOBs. Cushman & Wakefield reported average MOB vacancy rates nationally at a tight 7.5% at the end of 2023, significantly lower than the broader office market.
In terms of investment, MOBs remain a stable asset class. Major players like Harrison Street Real Estate Capital continue to be active. In October 2023, Harrison Street announced a joint venture with a leading national healthcare provider to acquire and develop a portfolio of MOBs across the Sun Belt region, highlighting the appeal of strategic partnerships and growth markets. MOBs offer attractive cap rates compared to traditional office, often ranging from 5.5% to 6.5% for core assets, reflecting their stable income streams and lower volatility.
RadCRE Perspective
Majid Radaei, Founder of RAD Commercial Realty, notes: "While the enthusiasm around life sciences might have cooled slightly from its 2021 peak, the underlying fundamentals are stronger than ever. We're seeing a flight to quality and mission-critical assets. For investors with a long-term view, these sectors represent a compelling opportunity, especially as some of the frothier speculative development has pulled back. On the financing side, lenders view these assets favorably due to their specialized nature and typically robust tenant credits. We're actively working with clients who are structuring attractive financing packages using a blend of conventional and sometimes even agency debt for MOBs, and bridge financing with strong equity partners for life sciences projects that can demonstrate strong pre-leasing or existing in-place cash flow. The key is understanding the nuances of how these facilities are leased and valued—it’s not just square footage, it’s highly specialized infrastructure and tenant covenants that drive value. I wouldn't be surprised to see cap rates compress further on best-in-class assets in the coming years as capital continues to seek stable, recession-resistant returns."
Long-Term Outlook
The long-term outlook for both life sciences and MOB investments remains positive. The confluence of demographic shifts, continuous innovation in healthcare, and the essential nature of these services provides a robust foundation for sustained performance. As such, institutional investors are likely to continue allocating significant capital to these sectors, viewing them as cornerstones of a diversified real estate portfolio.
Tags: life sciences real estate, medical office building investment, institutional CRE investment, healthcare real estate, RadCRE capital markets
Sources: JLL 2024 Life Sciences Outlook, Cushman & Wakefield Q4 2023 MOB Report, Blackstone, Harrison Street Real Estate Capital, Commercial Observer